The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia

Inclusion Criteria:

1. Males or females ≥ 18 years old and ≤55 years old

2. Subjects are in good health as judged by the investigator.

3. Diagnosed with by a dermatologist with moderate androgenetic alopecia.

4. Subject is seeking treatment for androgenetic alopecia.

5. Subject has never previously used finasteride or minoxidil or has consistently used
finasteride or minoxidil for at least 1 year.

6. Subjects who are willing and have the ability to understand and provide informed
consent for participation in the study and are able to communicate with the
investigator.

Exclusion Criteria:

1. Other than androgenetic alopecia, evidence of another skin condition affecting the
treatment area that would interfere with clinical assessments.

2. Subjects who are unwilling to avoid initiating treatment with minoxidil or finasteride
for the duration of the study; or in subjects who have been treated with minoxidil or
finasteride for at least 1 year, unwilling to avoid changes in the dosing regimen of
these medications for the duration of the study.

3. Willing to refrain from washing hair or using hair product 24 hours before and after
treatment visits

4. History of a clinically significant hematologic disorder as determined by the
investigator.

5. Subjects currently receiving anticoagulant or anti-platelet therapy.

6. Subjects on daily Aspirin therapy for cardiovascular disease.

7. Subjects with chronic NSAID use, unable to wean off.

8. Subject is known to be HIV positive.

9. History of recurrent facial or labial herpes simplex infection

10. History of hypertrophic scars or keloids

11. Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia,
osteogenesis imperfecta, etc.

12. Subjects who have any requirement for the use of local or systemic steroids or other
immunosuppressive agent

13. Pregnant or breast feeding

14. Uncooperative patients or patients with neurological disorders who are incapable of
following directions or who are predictably unwilling to return for follow-up
examinations.

15. Subjects who are unable to understand the protocol or give informed consent.